Trends in Internet Searches for Cannabidiol (CBD) in the United States Eric C. Leas, Alicia L. Nobles, PhD, Theodore L. Caputi, Mark Dredze, DaveyM. Smith, JohnW. Ayers JAMA Network Open, 2019, 2, (10), e1913853. doi: 10.1001/jamanetworkopen.2019.13853 Introduction Cannabidiol (CBD) is widely promoted as a panacea. For example, the cannabis brand MedMen claims CBD treats acne, anxiety, opioid addiction, pain, and menstrual problems.1 However, the US Food and Drug Administration has only approved highly purified CBD (Epidiolex) for treating epilepsy. To our knowledge, there is currently no population-focused surveillance of public interest in CBD. Consequently, many question whether CBD should be prioritized by public health leaders [...]
Lire la suiteConsumption of Ayahuasca by Children and Pregnant Women : Medical Controversies and Religious Perspectives Beatriz Caiuby Labate Journal of Psychoactive Drugs, 2011, 43, (1), 27-35. DOI: 10.1080/02791072.2011.566498 Abstract In 2010, the Brazilian Government agency responsible for drug-related issues formulated official Resolutions that categorized the consumption of ayahuasca by pregnant women and children in the Santo Daime and Uniâo do Vegetal ayahuasea-based religions as an "exercise of parental rights." Although ayahuasca groups do enjoy a relative degree of social legitimacy and formal legal recognition in Brazil, the participation of pregnant women and children nevertheless continues to provoke heated discussion. This article raises the main issues involved [...]
Lire la suiteEntheogen : Ultimate Guide To Entheogens Rafaelia Cleary, Relax Like A Boss, 2019 https://relaxlikeaboss.com/entheogen/ What is an entheogen? What do entheogenic substances do? And how does entheogen therapy work? We’ll answer all of these questions plus much more in our ultimate guide below… Table of Contents What Is An Entheogen? There are many people who find words like ‘spiritual’ and ‘psychedelic’ to be a little odd. However, they can’t deny the use of psychoactive sacraments in various religious practices. An entheogen is a type of psychoactive substance that plenty of shamanic and religious activities use. These psychoactive substances are typically the derivatives of plant sources. But now since the organic chemistry is in [...]
Lire la suitePsychiatric Comorbidity of Cannabis Use Disorder David Gorelick In book : "Cannabis Use Disorders", January 2019 DOI : 10.1007/978-3-319-90365-1_13 Abstract : Objective : This chapter reviews the epidemiology and treatment of cannabis use disorder (CUD) with psychiatric comorbidity. Methods : We summarize the findings of English-language epidemiological studies reporting current (past-year) comorbidity and of controlled clinical trials of treatment in which the majority of participants had diagnosed CUD and a specific comorbid disorder. Results : There is substantial CUD comorbidity among community-dwelling adults with major psychiatric disorders: 4–6% for depression, 14% for bipolar disorder, 5% for anxiety disorder, and 16% for schizophrenia. Conversely, there is substantial psychiatric [...]
Lire la suiteEndocannabinoid System in Neurological Disorders (Endocannabinoid System and Neurodegeneration) Roberta Ranieri, Chiara Laezza, Maurizio Bifulco, Daniela Marasco and Anna Maria Malfitano Recent Patents on CNS Drug Discovery, 2015, Vol. 10, No. 2, 24 p. Abstract : Background : Several studies support the evidence that the endocannabinoid system and cannabimimetic drugs might have therapeutic potential in numerous pathologies. These pathologies range from neurological disorders, atherosclerosis, stroke, cancer to obesity/metabolic syndrome and others. Methods : In this paper we review the endocannabinoid system signaling and its alteration in neurodegenerative disorders like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease and discuss the main findings about the use [...]
Lire la suiteEndocannabinoid System Aleksandra Tarasiuka, Maciej Salagaa, and Jakub Fichna, Medical University of Lodz, Lodz, Poland Encyclopedia of Gastroenterology, 2nd Edition © 2019 Elsevier Inc. All rights reserved. https://doi.org/10.1016/B978-0-12-801238-3.65635-0 Introduction 1 Cannabinoids and Their Role in the Physiological and Pathophysiological Processes in the GI Tract 3 Physiological Conditions 3 Gut motility 3 Gastric secretion and emptying 3 Pathophysiological Conditions 4 IBS 4 IBD 5 Colon cancer 5 Peptic ulcer disease 5 Endocannabinoid System and Its Interplay With Other Systems 5 Cholecystokinin 5 Endovanilloids 6 Opioids 6 Endocannabinoid System and Gut Microbiota 6 Conclusion 7 Acknowledgments 7 References Introduction Endocannabinoid system (ECS) is one of the crucial physiological systems that may be targeted to improve human health. Endocannabinoids and their receptors are localized in various organs [...]
Lire la suiteBIBLIOGRAPHIE : Cannabinoïdes, Dépression et Troubles de l’Humeur Docteur Christian SUEUR, GRECC, novembre 2019.
Lire la suitePlastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders Alline C. Campos, Manoela V. Fogaça, Franciele F. Scarante, Sâmia R. L. Joca, Amanda J. Sales, Felipe V. Gomes, Andreza B. Sonego, Naielly S. Rodrigues, Ismael Galve-Roperh, and Francisco S. Guimarães Frontiers in Pharmacology, 2017. doi: 10.3389/fphar.2017.00269 Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. [...]
Lire la suiteCannabinoids, Neurogenesis and Antidepressant Drugs : Is there a Link ? Manoela Viar Fogaça, Ismael Galve-Roperh, Francisco Silveira Guimarães and Alline Cristina Campos Current Neuropharmacology, 2013, 11, 263-275 Abstract Similar to clinically used antidepressants, cannabinoids can also regulate anxiety and depressive symptoms. Although the mechanisms of these effects are not completely understood, recent evidence suggests that changes in endocannabinoid system could be involved in some actions of antidepressants. Chronic antidepressant treatment modifies the expression of CB1 receptors and endocannabinoid (EC) content in brain regions related to mood and anxiety control. Moreover, both antidepressant and cannabinoids activate mitogen-activated protein (MAP) kinase and phosphoinositide 3- kinase(PI3 [...]
Lire la suiteRevisiting Wasson’s Soma : Exploring the Effects of Preparation on the Chemistry of Amanita muscaria. Kevin FEENEY Journal of Psychoactive Drugs, 2010, 42, (4), 499-506 In 1968 R. Gordon Wasson first proposed his groundbreaking theory identifying Soma, the hallucinogenic sacrament of the Vedas, as the classic spotted fairy tale mushroom – Amanita muscaria. While Wasson’s theory is compelling on many levels he neglected to explain how the pressing and filtering of Soma, as described in the Rig Veda, supported his theory of Soma’s identity. This omission has led to several criticisms of his theory, including: (1) that such an elaborate process of extraction [...]
Lire la suite